Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Metastatic Leiomyosarcoma

Next Previous
X
Search
Trial Profile

A Randomized Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Metastatic Leiomyosarcoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Onfekafusp alfa (Primary) ; Doxorubicin
  • Indications Leiomyosarcoma
  • Focus Therapeutic Use
  • Acronyms FIBROSARC US; FIBROSARC USA
  • Sponsors Philogen

    • Most Recent Events

    • 07 Nov 2023 According to a Philogen media release, this trial is underway at 9 clinical centers in the United States.
    • 07 Apr 2022 Inclusion criteria has been updated to removed the following cancers- histiocytoma, liposarcoma, Fibrosarcoma and Angiosarcoma. thus the focus of the study is only on stage 4 high-grade leiomyosarcoma. Upper age limit is extended from 75 to 100 years.
    • 07 Apr 2022 Planned End Date changed from 1 Sep 2022 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top